Krsnaa Diagnostics Limited

rs,

O GOOD ... ® Date: 04th August, 2022 BSE Ltd. Corporate Service Department pt Floor, P.J. Towers, Dalal Street, Mumbai 400 001 Scrip ID: KRSNAA Scrip Code: 543328 Dear Sir/Madam, The Nationa

rs 3

s Total Assets to be Deployed* 7 States 41 CT Scan 2 MRI Scan 24 | 190 Labs | Collection Centers 3 Core Business Continues to Grow In Q1 FY23, Core Revenue up by 10.5% y-o-y despite high base in Q1

10.5%

| 190 Labs | Collection Centers 3 Core Business Continues to Grow In Q1 FY23, Core Revenue up by 10.5% y-o-y despite high base in Q1 FY22 due to second wave of Covid-19 EBITDA margins remained strong a

25.1%

-o-y despite high base in Q1 FY22 due to second wave of Covid-19 EBITDA margins remained strong at 25.1% and improvement is expected from upcoming quarters with operationalization of new centres Total Re

99.0%

Covid-19 Revenue1 Rs. Million 1,325 1,082 1,129 +10.5% YoY 1,062 1,019 1,126 306 -99.0% YoY Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 20 3 EBITDA2 Prof

31.7%

Q1FY23 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 20 3 EBITDA2 Profit After Tax 420 31.7% 284 26.2% 283 25.1% 216 179 16.3% 16.6% 142 12.6% Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q

26.2%

Y22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 20 3 EBITDA2 Profit After Tax 420 31.7% 284 26.2% 283 25.1% 216 179 16.3% 16.6% 142 12.6% Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23

16.3%

Y22 Q1FY23 20 3 EBITDA2 Profit After Tax 420 31.7% 284 26.2% 283 25.1% 216 179 16.3% 16.6% 142 12.6% Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Notes: 1. Covid-19 Business i

16.6%

FY23 20 3 EBITDA2 Profit After Tax 420 31.7% 284 26.2% 283 25.1% 216 179 16.3% 16.6% 142 12.6% Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Notes: 1. Covid-19 Business is inclu

12.6%

EBITDA2 Profit After Tax 420 31.7% 284 26.2% 283 25.1% 216 179 16.3% 16.6% 142 12.6% Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Notes: 1. Covid-19 Business is including Covid al

0%

is including Covid allied tests 2. EBITDA is excluding CSR and ESOP expenses Revenue Mix COVID, 0% Pathology, 38% Tele- Reporting, 10% Radiology, 52% 4 Core Business Volumes Continues to Gro

38%

id allied tests 2. EBITDA is excluding CSR and ESOP expenses Revenue Mix COVID, 0% Pathology, 38% Tele- Reporting, 10% Radiology, 52% 4 Core Business Volumes Continues to Grow Tests In Milli

“Maturity is on the basis of the project start date 3.”

“28 Krsnaa Diagnostics Edge One of the Fastest Growing Diagnostics Service Provider in the country Extensive Geographic Footprint Strong Brand Equity Scalable and Agile Business Model Disruptive Pricing Stakeholder Value Creation Total Centre count increased at a CAGR of 32% from 682 in FY18 to 2050+ in FY21 Centres across India with presence in 14 States.”

Notes

6

Note

2

Regional Chains due to

1

Entry Limitations

1

For further information please contact

1

Notes

1. Covid-19 Business is including Covid allied tests 2. EBITDA is excluding CSR and ESOP expenses Revenue Mix COVID, 0% Pathology, 38% Tele- Reporting, 10% Radiology, 52% 4 Core Business Volumes Continues to Grow Tests In Million Total Number of Tests 4.78 5.42 ▪ Tests volume growth visible in all modalities led by sharp increase in Tele-reporting tests 3.60 Q1FY22 Q4FY22 Q1FY23 ▪ Higher awareness and visibility of Krsnaa’s diagnostics centres ▪ High quality services at disruptive prices driving patient and tests count Radiology Tests Tele-Reporting Tests Pathology Tests Covid-19 Tests1 3.81 3.42 1.32 1.06 2.15 0.23 0.25 0.28 0.56 0.66 0.05 0.01 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23

Note

1. Covid-19 Business is including Covid allied tests 5 Management Perspective Commenting on the business, Ms. Pallavi Bhatevara, Managing Director, said: “Krsnaa diagnostics started a new fiscal year on a strong note with 4 new tender wins being added to its portfolio. I am pleased to inform that with recent wins we have entered in two new states: New Delhi and Tripura. We are also proud to have won Maharashtra mega tender wherein Krsnaa needs to deploy 31 CT scan and operate 8 government installed CT scan across 39 government hospitals. As of today, Krsnaa needs to deploy 41 CT scan, 2 MRI, set up 24 labs and 190 collection centres under various contracts excluding the ones mentioned in RHP. The recent contract wins reflect Krsnaa inhouse teams' capability to meticulously follow the bidding process, fulfil requirements and win the contract. With these projects in line, Krsnaa continues to diversify its presence into new geographies and has built a strong foundation for delivering a lo

Notes

1. Covid-19 Business is including Covid allied tests 2. 3. EBITDA is excluding CSR and ESOP expense EBIT including Other Income Q1FY23 Q1FY22 Y-o-Y Growth Q4FY22 Q-o-Q Growth 1,126 3 1,129 46 1,175 283 25.1% 201 17.8% 142 12.6% 4.51 1,019 306 1,325 32 1,357 420 31.7% 348 26.2% 216 16.3% 10.5% (99.0)% (14.8)% 43.3% (13.4)% (32.7)% (42.3)% (34.2)% 1,062 20 1,082 41 1,123 284 26.2% 217 20.0% 179 16.6% 5.9% (85.1)% 4.3% 13.3% 4.6% (0.4)% (7.5)% (20.8)% 7.94 (43.2)% 5.40 (16.5)% 8 Business Overview 9 Track Record of Successful Fast-Pace Expansion Started operating 12 centres in Himachal Pradesh in Public Private Partnership Incorporated the Company with 2 radiology centers 2013 2011 2017 Expanded footprint Centres – 50 States – 4 Pan India Expansion Centres – 664 States – 12 2018 2020 2019 Expansion Centres – 1,300+ States – 13 Expanded strategic tie-up with Private Hospital Private Centres – 14 Expansion Centres – 1,800+ States – 14 Won contract for Punjab Radiology and Pathology 2022 2021

Regional Chains due to

▪ ▪ Krsnaa’s expertise and scale of business Access to high-cost radiology machines at relatively lower prices

Entry Limitations

▪ High capex, low opex model is tough to enter ▪ Disruptive pricing model makes it tough for competition to compete ▪ Larger chains focused on pathology tests Note: Peer information is based on publicly available information as on 31st March, 2022 and for representative purposes only 13 High Quality Diagnostic Services at Disruptive Prices Krsnaa Offers Tests at 45-60% Lower than Market Rates Segment Test Player 1 Player 2 Player 3 Krsnaa RDL RDL PTH PTH PTH PTH PTH PTH CT Brain MRI Brain CBC Blood Sugar Thyroid Vitamin D Vitamin B12 HbA1C 4,500 8,000 250 85 500 1,500 1,000 550 4,500 8,250 250 80 550 1,250 1,100 440 3,500 7,000 200 70 550 1,450 1,300 400 2,000 3,500 146 26 216 595 243 141 % from min price (43%) (50%) (27%) (63%) (57%) (52%) (76%) (65%) high Krsnaa diagnostics services at disruptive prices Diagnostics offers quality Well placed to withstand any industry price caps as well pricing pressure on tests Cost Disruption… Leading to a Virtuous Cycle.. Low fixed cost of operatio

Notes

1. 2. Maturity is on the basis of the project start date 3. Return on Capital Employed calculated as (EBIT including Other Income / Gross Block) 22 Fully Geared to Disrupt the Growing Retail Market Retail Market Expansion Strategy Pathology through Krsnaa Business Associates Wellness 5 key wellness and 5 key illness package Launch of specialized tests- Genomics Expansion in Retail Market Hospital Lab Management Tele reporting support – For key alliances Franchisee Model Pick-Up-Points (Nursing Homes, Hospitals, small and mid- sized Laboratories, SIS, HLM, DOL) Awareness (Camps and Corporates, Wellness & Illness Packages) PACH Model Collection Centre Network and Franchisee CCs (Krsnaa Business Associates- KBA) Home Collection Services 23 Expanding B2C Pathology Service Offerings Capitalizing on the extensive infrastructure of Pathology Diagnostics and extending it to end consumers 613 Pathology Centres 52 561 Processing Labs Collection Centres ▪ Expanding B2C pathology diagnostic servic